Healthcare: How to Invest in the Sector, Which Companies and Which ETFs

Imagine a sector where demand is practically independent of the economic cycle. Illness doesn't wait for a recession. Surgery is not postponed because of high interest rates. This is the basic argument for healthcare as a defensive portfolio component — and it is true. But defensive does not mean risk-free. The healthcare sector has its own dragon: it's called regulation. And regulation always arrives without warning.

How the sector divides and why it matters

Healthcare is an umbrella term for four distinct sub-sectors that behave differently and respond to different factors:

• Health insurers (UnitedHealth, CVS Health, Humana) — operate health plans, manage policyholder databases and provide managed care services. Sensitive to legislation, decisions on the scope of insurance coverage and political pressure to reduce profits.
• Pharmaceutical companies (Johnson & Johnson, Pfizer, AbbVie, Merck) — research, manufacture and market drugs. Patent protection is critical — when patents expire, generic competition enters and revenues from a specific division drop dramatically. This phenomenon is called the patent cliff.
• Medical devices and equipment (Medtronic, Abbott, Stryker) — implants, diagnostic instruments, surgical tools and monitoring systems. Relatively defensive, lower patent risk than pharmaceuticals, but require regulatory approval.
• Biotechnology — binary risk from clinical trials, a complex world discussed in a separate article on biotech. A different calibre of risk from the remaining sub-sectors.

When you buy XLV or a similar sector fund, you buy a mix of all of the above. Weights are market-capitalisation-based — UnitedHealth, J&J and Eli Lilly tend to be among the largest positions. Know what you are buying before you click confirm.

UnitedHealth Group: strength and target

UnitedHealth Group (UNH) is the world's largest health insurer with a market capitalisation in the hundreds of billions of dollars. The company runs the United Healthcare insurance plan covering tens of millions of policyholders and the data and technology division Optum, which processes healthcare data and provides analytical services to hospitals. It regularly increases dividends — it is often listed among healthcare dividend aristocrats.

But you must also monitor this company from a regulatory risk perspective. The American debate on the healthcare system — insurer costs, denial of claims, drug margins — recurs every electoral cycle. Legislative change that regulated insurer profits or introduced a public insurance plan would directly threaten UNH's valuation.

This is not a hypothetical threat. UNH shares have repeatedly responded with sharp drops to political news and regulatory investigations. One Congressional bill, one FTC investigation, can move the share price 10–15%. For comparison, Lockheed Martin does not carry such political risk. Consciously owning insurers means consciously owning this risk factor.

J&J and the pharmaceutical division: patent cliff and the future

Johnson & Johnson (JNJ) underwent a fundamental transformation in recent years — it spun off the consumer goods division as a separate company, Kenvue, and focused on pharmaceuticals and medical devices. Strengths: diversified drug pipeline, stable dividends for over 60 years without interruption, strong balance sheet with low leverage.

Weakness: the patent cliff. The key immunosuppressant Stelara lost patent protection and generic competition is entering — revenues from this product will drop significantly. J&J must compensate the loss with new pipeline molecules. Research and development is enormously costly and not always successful. The company also carries historical legal liabilities from the talc case, where carcinogenic contamination was proven.

J&J is an example of a stable but slow investment more suited to conservative investors who appreciate stable dividends over capital growth. Significant share price appreciation requires a pipeline breakthrough — and that is always an uncertainty.

An ageing population as a structural tailwind

The demographic argument for healthcare is unquestionable. The average age of the population in the US, Europe and Japan is rising. Older people consume significantly more healthcare — more medications, more surgeries, more diagnostics, more long-term care. The baby boomer cohort is entering the 75+ age bracket and this group has average healthcare expenditures several times higher than those in their forties.

But this tailwind is so well known and long apparent that the market has largely priced it into valuations. This does not mean healthcare won't rise — it means don't expect cheap valuations just because of demographics. Demographics is a necessary condition for a fundamentally interesting sector, but alone it is not sufficient as an argument for buying at any price.

How healthcare fits into the portfolio

Healthcare historically has lower correlation with the overall equity market than the technology or consumer sector. In recessions it falls less, in bull markets it lags. This makes it a potentially interesting complement to a growth portfolio component for investors who want less overall portfolio volatility.

But it is not an emergency brake. In the 2008–2009 crash the healthcare sector also fell — just slightly less than the overall market. In 2022–2023 the sector held up relatively better, but in absolute terms it was not immune.

For a first portfolio the foundation is always a broad-market index — healthcare as a satellite makes sense only when the core is solid and well-diversified. XLV or its UCITS equivalent is one of the more conservative sector bets, but remember that even a conservative sector carries specific risks that a broad-market index naturally dampens through diversification.

Sub-sector comparison: what to add and what to skip

If you have decided on sector exposure, consider which sub-segment matches your risk profile. Medical devices and equipment (Medtronic, Stryker) are the least volatile part of healthcare — stable demand, lower regulatory risk than pharmaceuticals, no patent cliff in the classical sense. Pharmaceuticals and insurers offer higher potential but bring more pronounced regulatory and political risk. Biotech is a subject in its own right in a separate article. Healthcare as a whole through XLV or its UCITS equivalent is a compromise — the midpoint between the defensive calm of devices and the drama of pharmaceuticals. For a long-term investor that is not a bad position. And if you are still unsure, start with a basic understanding of risk categories — then decide whether a sector fund complements your portfolio or merely adds unnecessary complexity.